Keyphrases
Advanced Glycation End Products
100%
Age-matched
9%
Cardiovascular Disease Events
54%
Cardiovascular Events
100%
Cardiovascular Risk
9%
Chronic Kidney Disease
27%
Combined Antiretroviral Therapy (cART)
9%
Confidence Interval
9%
Cox Regression Analysis
9%
Diabetic Kidney Disease
9%
Healthy Volunteers
9%
HIV Infection
100%
HIV Patients
18%
HIV-1 Infection
9%
Hypertension
9%
Men Who Have Sex with Men
9%
Nadir CD4 Cell Count
18%
Oxidative Stress
9%
Patient Self-testing
9%
Prospective Cohort Study
9%
Regression Analysis
9%
Single Center
9%
Skin Autofluorescence
100%
Subclinical Cardiovascular Disease
9%
Type 1 Diabetes Mellitus (T1DM)
9%
Medicine and Dentistry
Advanced Glycation End-Product
100%
Antiretroviral Therapy
9%
Autofluorescence
100%
Cardiovascular Disease
72%
Cardiovascular System
100%
Cell Count
18%
Chronic Kidney Disease
27%
Diabetes
9%
Diabetes Mellitus
9%
Glycemic
9%
Human Immunodeficiency Virus
18%
Human Immunodeficiency Virus 1 Infection
9%
Human Immunodeficiency Virus Infection
100%
Men Who Have Sex with Men
9%
Oxidative Stress
9%
Proportional Hazards Model
9%
Prospective Cohort Study
9%
Volunteer
9%
Nursing and Health Professions
Advanced Glycation End Product
100%
Antiretroviral Therapy
12%
Cardiovascular Disease
100%
CD4 Lymphocyte Count
25%
Chronic Kidney Failure
37%
Confidence Interval
12%
Diabetes Mellitus
12%
Human Immunodeficiency Virus
25%
Human Immunodeficiency Virus 1 Infection
12%
Human Immunodeficiency Virus Infection
100%
Men Who Have Sex with Men
12%
Proportional Hazards Model
12%
Prospective Cohort Study
12%
Volunteer
12%
Immunology and Microbiology
Autofluorescence
100%
CD4 Lymphocyte Count
18%
Glycation
100%
Human Immunodeficiency Virus
9%
Human Immunodeficiency Virus 1
18%
Human Immunodeficiency Virus Infection
100%
Normal Human
9%
Oxidative Stress
9%
Biochemistry, Genetics and Molecular Biology
Advanced Glycation End-Product
100%
Autofluorescence
100%
CD4 Lymphocyte Count
18%
Human Immunodeficiency Virus
100%
Human Immunodeficiency Virus 1
18%
Normal Human
9%
Oxidative Stress
9%
Prospective Cohort Study
9%